Travere Therapeutics Inc. (TVTX)
NASDAQ · Healthcare
Travere Therapeutics Inc. Operating Income 2011–2025
Travere Therapeutics Inc. annual/quarterly operating income history and growth rate from 2016 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Travere Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -36.9 M, a 13.50% decrease year-over-year.
- Travere Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -67.3 M, a 81.08% decrease year-over-year.
- Travere Therapeutics Inc. annual operating income for 2025 was -62.8 M, a 80.60% decrease from 2024.
- Travere Therapeutics Inc. annual operating income for 2024 was -323.8 M, a 16.57% decrease from 2023.
- Travere Therapeutics Inc. annual operating income for 2023 was -388.1 M, a 21.36% increase from 2022.
- Travere Therapeutics Inc. annual operating income for 2022 was -319.8 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Travere Therapeutics Inc. Operating Income — FAQ
Travere Therapeutics Inc. (TVTX) operating income over the last 12 years — annual and quarterly figures with year-over-year growth and charts.
What is Travere Therapeutics Inc.'s operating income?
Travere Therapeutics Inc. (TVTX) reported operating income of -$63M for fiscal 2025.
Where can I see TVTX's operating income history?
The chart and table above show Travere Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.